Form 4: MBX Biosciences Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Steven L. Hoerter was granted 12,500 stock options in MBX Biosciences, Inc. as part of his compensation.
Summary
- Director Steven L. Hoerter received a grant of 12,500 stock options on June 4, 2026.
- The options have an exercise price of $30.91 per share.
- The options are set to expire on June 4, 2036.
- The reporting person maintains direct ownership of 11,938 shares and indirect ownership of 20,000 shares via a revocable trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive effect of new option grants on existing shareholders.
Risks
- Market volatility affecting the value of the underlying common stock.
- Vesting is contingent upon continued service to the company.
Future Outlook
The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders.
Industry Context
StockSavvy.ai notes that equity grants for non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.
Comparison to Industry Standards
- The grant structure is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
- Vesting schedules tied to annual meetings are common industry practice for non-employee directors.
Related Party Transactions
- The reporting person serves as trustee for the Steven L. Hoerter Revocable Trust, which holds 20,000 shares.
Stakeholder Impact
- Minimal impact on shareholders; represents standard director compensation.
Next Steps
- Vesting of the 12,500 stock options on the earlier of the one-year anniversary or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2018-11-02 | Date of the Steven L. Hoerter Revocable Trust. |
| 2026-06-04 | Transaction date of the stock option grant. |
| 2026-06-05 | Filing date of the Form 4. |
| 2036-06-04 | Expiration date of the granted stock options. |
Keywords
MBX Biosciences, Insider Trading, Form 4, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.